ClinicalTrials.gg
CompletedNCT01585025OBADIAH1Updated Mar 10, 2023Results posted

Obeticholic Acid in Bile Acid Diarrhoea

A Phase 2 interventional study of Obeticholic acid in Primary Bile Acid Malabsorption, Secondary Bile Acid Malabsorption and Chronic Diarrhoea, sponsored by Imperial College Healthcare NHS Trust. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-10.

Sponsored by Imperial College Healthcare NHS Trust · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The investigators propose to develop studies of obeticholic acid (OCA) in patients with bile acid diarrhoea. OCA is a semisynthetic bile acid, also known as 6αethylchenodeoxycholic acid or INT747,and is a potent farnesoid X receptor (FXR) agonist. Preliminary data suggests that patients with bile acid diarrhoea have impaired production of the ileal hormone Fibroblast Growth Factor 19 (FGF19). FGF19 is stimulated by FXR agonists, and regulates bile acid synthesis. This study is a pilot, proof-of-concept, open-label study to investigate whether OCA can stimulate FGF19 in bile acid diarrhoea patients to provide a safe and effective treatment.

Read the detailed description

Bile acid diarrhoea (BAD) is an under-recognised but common condition of chronic watery diarrhoea. BAD may be secondary to ileal disease affecting the reabsorption and the enterohepatic circulation of bile acids (bile acid malabsorption) or can be an idiopathic, primary BAD (PBAD). In work published in 2009, we described a new mechanism to explain this syndrome of primary BAD.

Blood levels of the hormone fibroblast growth factor 19 (FGF19) are reduced in primary and secondary BAD, producing impaired feedback inhibition of bile acid synthesis, leading to excess faecal bile acids, which then produce diarrhoea by stimulating colonic secretion. FGF19 is synthesised in the ileum and we have shown transcription is markedly induced by farnesoid X receptor(FXR) agonists such as chenodeoxycholic acid, an abundant natural bile acid. More potent FXR agonists are logical diagnostic and therapeutic agents for this condition, and obeticholic acid (OCA), which is 100x more potent than chenodeoxycholic acid, has recently been developed. It has been used in phase II studies in primary biliary cirrhosis and in non-alcoholic steatohepatitis where a relatively common side-effect was constipation.

We aim to investigate the effects of OCA in patients with primary and secondary BAD to determine whether FGF19 is able to be stimulated in these conditions. We will compare these responses to those in control patients with chronic diarrhoea but without evidence of BAD. It is possible in BAD that the defect in FGF19 levels is due to an inability to respond to FXR stimulation (particularly likely in secondary BAD after ileal resection). Patients with primary BAD may be able to respond and benefit from an increase in FGF19 levels.

This study aims to obtain pilot data on the effects of OCA on FGF19, other markers of bile acid metabolism and patient symptoms including diarrhoea. These are early phase II, proof of concept studies.

02

Conditions studied

  • Primary Bile Acid Malabsorption
  • Secondary Bile Acid Malabsorption
  • Chronic Diarrhoea

Keywords

  • Primary bile acid malabsorption
  • Secondary bile acid malabsorption
  • Chronic diarrhoea
  • Obeticholic acid
  • SeHCAT
  • FXR
  • FGF19
03

In context

Lead sponsor

Imperial College Healthcare NHS Trust is the lead sponsor of 80 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Patients aged 18 - 80 who present at routine Gastrointestinal Outpatient Clinics at Hammersmith and Charing Cross Hospitals with chronic diarrhoea, defined as an average stool frequency of at least three per day, of Bristol Stool Type 6 or 7, for at least 3 months. Previous routine SeHCAT testing to establish the presence or absence of bile acid diarrhoea (BAD) unless there is evidence of TI disease/ resection. BAD will be defined as SeHCAT 7-day retention of less than 15% or diarrhoea in presence of TI disease/ resection. Study subjects will be grouped as having secondary BAD, due to ileal resection or Crohn's disease, or primary BAD, with no obvious cause. The third, control group having chronic diarrhoea but with normal SeHCAT retention (greater than 15%).

Female patients must be , surgically sterile, or if premenopausal, be prepared to use ≥ 1 effective (≤ 1% failure rate) method of during the trial and for 15 days after the last dose of OCA. Male subjects with female partners of must use ≥ 1 effective method of contraception. Effective methods of contraception are considered to be: 1. Established use of oral, injected or implanted hormonal methods of contraception. 2. Placement of an intrauterine device (IUD) or intrauterine system (IUS). 3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. 4. Male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). 5. True abstinence: When this is in line with the preferred and usual lifestyle of the subject.

Exclusion Criteria

  • Patients with other diagnoses leading to diarrhoea, including colorectal neoplasia, ulcerative colitis, coeliac disease, chronic pancreatitis, drug-induced diarrhoea or active infection.
  • Patients who have not been investigated by standard clinical assessments to exclude these disorders.
  • Treatment with bile acid sequestrants (colestyramine, colestipol, colesevelam) for 2 weeks before the first dose of OCA. Loperamide use will be allowed up to 16mg/d in divided doses.
  • Previous biliary surgery, excluding cholecystectomy.
  • Abnormal , (ALT), aspartate aminotransferase (AST) or alkaline phosphatase on more than 1 occasion.
  • Chronic liver disease
  • Chronic kidney disease
  • Active, serious medical disease with likely less than 5 years
  • Active substance abuse including inhaled or injection drugs in the year prior to screening
  • Allergy to obeticholic acid.
  • Pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use effective birth control during the trial, breast feeding. Pregnancy will be assessed with urinary β-hCG pregnancy test.
  • Participation in an new drug trial in the 30 days before randomisation
  • Any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of the study
  • Failure to give
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Primary BAD

    Defined as SeHCAT \<10% without other causes such as Crohn's disease and/or ileal resection

    Drug: Obeticholic acid

  • Experimental
    Secondary BAD

    With Crohn's disease or ileal resection

    Drug: Obeticholic acid

  • Experimental
    Idiopathic Diarrhoea Controls

    Chronic diarrhoea with SeHCAT \>15% and no Crohn's or ileal resection

    Drug: Obeticholic acid

Interventions

  • Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.

    Also known as: INT-747, 6 ethyl chenodeoxycholic acid

06

What researchers measure

Primary outcomes

  1. Changes in Fasting FGF19

    The primary outcome measure is the change over 2 weeks in fasting serum fibroblast growth factor (FGF19) in 3 groups of patients: primary bile acid diarrhoea, secondary bile acid diarrhoea, and a control population of patients with chronic diarrhoea but with normal bile acid retention.

    Time frame: Day 0, Day 15

Secondary outcomes

  1. Changes in Non-fasting Response of FGF19 to OCA

    Change in dynamic response of FGF19 in 6 hours following OCA administration; at start and end of 15 day OCA test period.

    Time frame: Day 0, Day 15

  2. Changes in Fasting 7α-hydroxy-4-cholesten-3-one

    Change in fasting 7α-hydroxy-4-cholesten-3-one before and after 15 day administration of OCA.

    Time frame: Day 0, Day 15

  3. Changes in Serum Total Bile Acids.

    Dynamic changes of total bile acids over 6 hour period following OCA administration before and after 15 day OCA period.

    Time frame: Day 0, Day 15

  4. Changes in Stool Frequency

    Change in total number of stool episodes reported per week between week 2 (baseline) and week 4 (week 2 of treatment)

    Time frame: Week 2, Week 4

  5. Changes in Mean Stool Form

    Change in mean stool form reported per week between week 2 (baseline) and week 4 (week 2 of treatment) using the Bristol Stool Form Scale (range of scores 1 to 7). High scores are a worse outcome (7=liquid stools).

    Time frame: Week 2, Week 4

  6. Change in Stool Index

    Change in index calculated on a weekly basis, between week 2 (baseline) and week 4 (week 2 of treatment). Index calculated as (\[weekly stool frequency x mean Bristol Stool Form Scale score\] = Loperamide use \[weekly mg x 3\]). Individual scores ranged from 25 to 1095, with higher scores being worst.

    Time frame: Week 2, Week 4

07

Results

Posted Sep 13, 2019
Limitations and caveats
Recruitment in the idiopathic chronic diarrhoea control group did not reach the prespecified number of 10 due to dropouts. Of the 8 subjects recruited, one failed to return diaries that could be analysed.

Participant flow

Participant flow — Overall Study
MilestonePrimary BADSecondary BADIdiopathic Diarrhoea Controls
Started101312
Completed10108
Not completed034
Withdrew: Withdrawal by subject034

Outcome measures

PrimaryChanges in Fasting FGF19

The primary outcome measure is the change over 2 weeks in fasting serum fibroblast growth factor (FGF19) in 3 groups of patients: primary bile acid diarrhoea, secondary bile acid diarrhoea, and a control population of patients with chronic diarrhoea but with normal bile acid retention.

Time frame:
Day 0, Day 15
Reported as:
Median · percentage increase of baseline
Changes in Fasting FGF19
percentage increase of baselinePrimary BADSecondary BADIdiopathic Diarrhoea Controls
Changes in Fasting FGF1971 (9 to 102)25 (-6 to 140)130 (-14 to 304)
Statistical analysis
  • Primary BAD · Wilcoxon (Mann-Whitney) · p = 0.007
  • Secondary BAD · Wilcoxon (Mann-Whitney) · p = 0.11
  • Idiopathic Diarrhoea Controls · Wilcoxon (Mann-Whitney) · p = 0.12
SecondaryChanges in Non-fasting Response of FGF19 to OCA

Change in dynamic response of FGF19 in 6 hours following OCA administration; at start and end of 15 day OCA test period.

Time frame:
Day 0, Day 15
Reported as:
Median · percentage change
Changes in Non-fasting Response of FGF19 to OCA
percentage changePrimary BADSecondary BADIdiopathic Diarrhoea Controls
Changes in Non-fasting Response of FGF19 to OCA11.6 (-23.6 to 57.8)14.6 (-22.7 to 49.0)32.4 (15.1 to 38.4)
Statistical analysis
  • Primary BAD · Wilcoxon (Mann-Whitney) · p = 0.72
  • Secondary BAD · Wilcoxon (Mann-Whitney) · p = 0.51
  • Idiopathic Diarrhoea Controls · Wilcoxon (Mann-Whitney) · p = 0.13
SecondaryChanges in Fasting 7α-hydroxy-4-cholesten-3-one

Change in fasting 7α-hydroxy-4-cholesten-3-one before and after 15 day administration of OCA.

Time frame:
Day 0, Day 15
Reported as:
Median · microgram/L
Changes in Fasting 7α-hydroxy-4-cholesten-3-one
microgram/LPrimary BADSecondary BADIdiopathic Diarrhoea Controls
Changes in Fasting 7α-hydroxy-4-cholesten-3-one-11.5 (-30.0 to -3.5)-27.5 (-56.3 to 0)-6.5 (-11.5 to -1.5)
Statistical analysis
  • Primary BAD · Wilcoxon (Mann-Whitney) · p = 0.03
  • Secondary BAD · Wilcoxon (Mann-Whitney) · p = 0.11
  • Idiopathic Diarrhoea Controls · Wilcoxon (Mann-Whitney) · p = 0.02
SecondaryChanges in Serum Total Bile Acids.

Dynamic changes of total bile acids over 6 hour period following OCA administration before and after 15 day OCA period.

Time frame:
Day 0, Day 15
Reported as:
Median · micromol/L
Changes in Serum Total Bile Acids.
micromol/LPrimary BADSecondary BADIdiopathic Diarrhoea Controls
Changes in Serum Total Bile Acids.-18.1 (-33.0 to -5.50)-2.0 (-17.5 to 0.08)-15.5 (-17.9 to -14.0)
Statistical analysis
  • Primary BAD · Wilcoxon (Mann-Whitney) · p = 0.02
  • Secondary BAD · Wilcoxon (Mann-Whitney) · p = 0.04
  • Idiopathic Diarrhoea Controls · Wilcoxon (Mann-Whitney) · p = 0.02
SecondaryChanges in Stool Frequency

Change in total number of stool episodes reported per week between week 2 (baseline) and week 4 (week 2 of treatment)

Time frame:
Week 2, Week 4
Reported as:
Median · stools per week
Changes in Stool Frequency
stools per weekPrimary BADSecondary BADIdiopathic Diarrhoea Controls
Changes in Stool Frequency-4.5 (-9.3 to -1.5)-2.5 (-15.8 to 1.8)3.0 (-3.0 to 7.0)
Statistical analysis
  • Primary BAD · Wilcoxon (Mann-Whitney) · p = 0.03
  • Secondary BAD · Wilcoxon (Mann-Whitney) · p = 0.17
  • Idiopathic Diarrhoea Controls · Wilcoxon (Mann-Whitney) · p = 0.31
SecondaryChanges in Mean Stool Form

Change in mean stool form reported per week between week 2 (baseline) and week 4 (week 2 of treatment) using the Bristol Stool Form Scale (range of scores 1 to 7). High scores are a worse outcome (7=liquid stools).

Time frame:
Week 2, Week 4
Reported as:
Median · Score on Bristol scale
Changes in Mean Stool Form
Score on Bristol scalePrimary BADSecondary BADIdiopathic Diarrhoea Controls
Changes in Mean Stool Form-0.71 (-1.54 to 0.10)-0.38 (-0.91 to -0.18)-0.46 (-0.91 to 0.86)
Statistical analysis
  • Primary BAD · Wilcoxon (Mann-Whitney) · p = 0.05
  • Secondary BAD · Wilcoxon (Mann-Whitney) · p = 0.04
  • Idiopathic Diarrhoea Controls · Wilcoxon (Mann-Whitney) · p = 0.74
SecondaryChange in Stool Index

Change in index calculated on a weekly basis, between week 2 (baseline) and week 4 (week 2 of treatment). Index calculated as (\[weekly stool frequency x mean Bristol Stool Form Scale score\] = Loperamide use \[weekly mg x 3\]). Individual scores ranged from 25 to 1095, with higher scores being worst.

Time frame:
Week 2, Week 4
Reported as:
Median · index score
Change in Stool Index
index scorePrimary BADSecondary BADIdiopathic Diarrhoea Controls
Change in Stool Index-37.5 (-52.3 to -22.8)-32.5 (-158.6 to -13.4)-5.5 (-30.0 to 20.0)
Statistical analysis
  • Primary BAD · Wilcoxon (Mann-Whitney) · p = 0.005
  • Secondary BAD · Wilcoxon (Mann-Whitney) · p = 0.03
  • Idiopathic Diarrhoea Controls · Wilcoxon (Mann-Whitney) · p = 0.61

Adverse events

Collected over Data were collected over the 6 weeks of the trial. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primary BAD0/10 (0%)0/10 (0%)0/10 (0%)
Secondary BAD0/10 (0%)0/10 (0%)3/10 (30%)
Idiopathic Diarrhoea Controls0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventPrimary BADSecondary BADIdiopathic Diarrhoea Controls
HeadacheNervous system disorders0/102/101/8
Constipation/abdominal painGastrointestinal disorders0/101/100/8

Baseline characteristics

Received any dose of medication

Age, Continuous
Age, Continuous(years)Primary BADSecondary BADIdiopathic Diarrhoea ControlsTotal
Median47 (24 to 74)45 (27 to 71)39 (25 to 68)41 (24 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Primary BADSecondary BADIdiopathic Diarrhoea ControlsTotal
Female77317
Male33511
Region of Enrollment
Region of Enrollment(participants)Primary BADSecondary BADIdiopathic Diarrhoea ControlsTotal
United Kingdom1010828
08

Study locations

2 sites
  • Hammersmith Hospital, Imperial College Healthcare NHS Trust
    London, W12 0HS, United Kingdom
  • Hammersmith Hospital
    London, W12 0HS, United Kingdom
09

References and documents

Publications

  • Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009 Oct;30(7):707-17. doi: 10.1111/j.1365-2036.2009.04081.x. Epub 2009 Jun 30. PubMed 19570102 ↗
  • Hofmann AF. The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy. Gastroenterology. 1967 Apr;52(4):752-7. No abstract available. PubMed 5337211 ↗
  • Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1189-94. doi: 10.1016/j.cgh.2009.04.024. Epub 2009 May 6. PubMed 19426836 ↗
  • Hofmann AF, Mangelsdorf DJ, Kliewer SA. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1151-4. doi: 10.1016/j.cgh.2009.07.026. Epub 2009 Aug 7. No abstract available. PubMed 19665580 ↗
  • Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest. 1997 Apr 15;99(8):1880-7. doi: 10.1172/JCI119355. PubMed 9109432 ↗
  • Montagnani M, Love MW, Rossel P, Dawson PA, Qvist P. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand J Gastroenterol. 2001 Oct;36(10):1077-80. doi: 10.1080/003655201750422693. PubMed 11589382 ↗
  • Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science. 1999 May 21;284(5418):1362-5. doi: 10.1126/science.284.5418.1362. PubMed 10334992 ↗
  • Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005 Oct;2(4):217-25. doi: 10.1016/j.cmet.2005.09.001. PubMed 16213224 ↗
  • Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med. 2006 Dec;260(6):530-6. doi: 10.1111/j.1365-2796.2006.01731.x. Erratum In: J Intern Med. 2008 Apr;263(4):459. PubMed 17116003 ↗
  • Brydon WG, Nyhlin H, Eastwood MA, Merrick MV. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol. 1996 Feb;8(2):117-23. doi: 10.1097/00042737-199602000-00005. PubMed 8723414 ↗
  • Johnston I, Nolan J, Pattni SS, Walters JR. New insights into bile acid malabsorption. Curr Gastroenterol Rep. 2011 Oct;13(5):418-25. doi: 10.1007/s11894-011-0219-3. PubMed 21805078 ↗
  • Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther. 2015 Jan;41(1):54-64. doi: 10.1111/apt.12999. Epub 2014 Oct 20. PubMed 25329562 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jan 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2019, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2012
First posted
Apr 25, 2012
Start
Apr 2012
Primary completionActual
Jan 2014
CompletionActual
Feb 2014
Results first posted
Sep 13, 2019
Last update
Mar 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01585025
Lead sponsor
Imperial College Healthcare NHS Trust
Responsible party
Sponsor
First posted
Apr 25, 2012
Start date
Apr 2012
Primary completion
Jan 2014
Completion
Feb 2014
Results posted
Sep 13, 2019
Last update
Mar 10, 2023

Study contacts

Julian RF Walters, MBBS MA FRCP
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obeticholic acid

Start the discussion